Pembrolizumab plus axitinib before kidney surgery for RCC with IVC tumor
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and sign the consent form
- Have kidney cancer with a clear-cell component (proven by biopsy/pathology)
- Be scheduled for “definitive” kidney surgery (nephrectomy) based on your urologist’s plan
- Have tumor stage cT3b/cT3c/cT4, with cN0 or cN1 and cM0 or cM1
- Be well enough for treatment (ECOG 0 to 2) and have urine protein below 2+ on dipstick (or under 2 grams/24 hours if further testing is needed)
- If you can get pregnant or make someone pregnant, have a negative pregnancy test within 14 days before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, lenvatinib and pembrolizumab, given before surgery to shrink kidney cancer that has spread into the large vein carrying blood to the heart (the vena cava). The goal is to see if this approach makes surgery more effective and improves outcomes.
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This Phase 2 trial studies whether adding axitinib to nivolumab (or giving nivolumab alone) can better control advanced clear-cell kidney cancer after standard initial treatment with nivolumab plus ipilimumab. It may help by extending response or slowing tumor growth while improving how long treatment works.
Hear when a new Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.